Particularly, a HER2-amplified cetuximab-resistant CRC xenograft model was tested against the dual EGFR/HER2 tyrosine kinase inhibitor, lapatinib, and anti-HER2 medication pertuzumab, with or without cetuximab. This evidence concerns the gene EGFR and colorectal carcinoma.